Association between RUNX3 promoter methylation and non-small cell lung cancer: A meta-analysis

Journal of Thoracic Disease

Volumn 6, Issue 6, 2014, Pages 694-705

  Liang, Yali ^a   He, Lianping ^a   Yuan, Hui ^a   Jin, Yuelong ^a   Yao, Yingshui ^a  

^a WANNAN MEDICAL COLLEGE   (China)

Author keywords

Meta analysis; Methylation; Non small cell lung cancer (NSCLC); Promoter; Runt related transcription factor 3 (RUNX3)

Indexed keywords

TRANSCRIPTION FACTOR RUNX3;

AGE DISTRIBUTION; ARTICLE; CANCER RISK; CANCER STAGING; HISTOPATHOLOGY; HUMAN; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; META ANALYSIS (TOPIC); PROMOTER REGION; PROTEIN METHYLATION; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SMOKING; TISSUE SECTION; TUMOR DIFFERENTIATION;

EID: 84904883437     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2014.04.09     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Stinchcombe TE, Socinski MA. Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 2009;6:233-41.
3. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9.
4. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
5. Risch A, Plass C. Lung cancer epigenetics and genetics. Int J Cancer 2008;123:1-7.
6. Shames DS, Girard L, Gao B, A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 2006;3:e486.
7. Herzog CR, Wang Y, You M. Allelic loss of distal chromosome 4 in mouse lung tumors localize a putative tumor suppressor gene to a region homologous with human chromosome 1p36. Oncogene 1995;11:1811-5.
8. Nomoto S, Haruki N, Tatematsu Y, et al. Frequent allelic imbalance suggests involvement of a tumor suppressor gene at 1p36 in the pathogenesis of human lung cancers. Genes Chromosomes Cancer 2000;28:342-6.
9. Hanai J, Chen LF, Kanno T, et al. Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter. J Biol Chem 1999;274:31577-82.
10. Lee JM, Kwon HJ, Bae SC, et al. Lung tissue regeneration after induced injury in Runx3 KO mice. Cell Tissue Res 2010;341:465-70.
11. Lee KS, Lee YS, Lee JM, et al. Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer. Oncogene 2010;29:3349-61.
12. Bae SC, Choi JK. Tumor suppressor activity of RUNX3. Oncogene 2004;23:4336-40.
13. Subramaniam MM, Chan JY, Soong R, et al. RUNX3 inactivation in colorectal polyps arising through different pathways of colonic carcinogenesis. Am J Gastroenterol 2009;104:426-36.
14. Chen W, Gao N, Shen Y, et al. Hypermethylation downregulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer. J Gastroenterol Hepatol 2010;25:823-31.
15. Homma N, Tamura G, Honda T, et al. Spreading of methylation within RUNX3 CpG island in gastric cancer. Cancer Sci 2006;97:51-6.
16. Yanada M, Yaoi T, Shimada J, et al. Frequent hemizygous deletion at 1p36 and hypermethylation downregulate RUNX3 expression in human lung cancer cell lines. Oncol Rep 2005;14:817-22.
17. Jeong P, Min BD, Ha YS, et al. RUNX3 methylation in normal surrounding urothelium of patients with nonmuscle-invasive bladder cancer: potential role in the prediction of tumor progression. Eur J Surg Oncol 2012;38:1095-100.
18. Lau QC, Raja E, Salto-Tellez M, et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 2006;66:6512-20.
19. Subramaniam MM, Chan JY, Soong R, et al. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat 2009;113:113-21.
20. de Freitas Cordeiro-Silva M, Stur E, Agostini LP, et al. Promoter hypermethylation in primary squamous cell carcinoma of the oral cavity and oropharynx: a study of a Brazilian cohort. Mol Biol Rep 2012;39:10111-9.
21. Park WS, Cho YG, Kim CJ, et al. Hypermethylation of the RUNX3 gene in hepatocellular carcinoma. Exp Mol Med 2005;37:276-81.
22. Jin M, Kawakami K, Fukui Y, et al. Different histological types of non-small cell lung cancer have distinct folate and DNA methylation levels. Cancer Sci 2009;100:2325-30.
23. Tan SH, Ida H, Lau QC, et al. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep 2007;18:1225-30.
24. Labeau SO, Van de Vyver K, Brusselaers N, et al. Prevention of ventilator-associated pneumonia with oral antiseptics: a systematic review and meta-analysis. Lancet Infect Dis 2011;11:845-54.
25. Kim TY, Lee HJ, Hwang KS, et al. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest 2004;84:479-84.
26. Castro M, Grau L, Puerta P, et al. Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med 2010;8:86.
27. Suzuki M, Wada H, Yoshino M, et al. Molecular characterization of chronic obstructive pulmonary diseaserelated non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling. Ann Surg Oncol 2010;17:878-88.
28. Yanagawa N, Tamura G, Oizumi H, et al. Inverse correlation between EGFR mutation and FHIT, RASSF1A and RUNX3 methylation in lung adenocarcinoma: relation with smoking status. Anticancer Res 2011;31:1211-4.
29. Tang Y, Wu F, Hu C. RUNX3 promoter hypermethylation and prognosis of early surgically resected non-small cell lung cancers. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2011;36:650-4.
30. Sato K, Tomizawa Y, Iijima H, et al. Epigenetic inactivation of the RUNX3 gene in lung cancer. Oncol Rep 2006;15:129-35.
31. Zhang Y, Wang R, Song H, et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett 2011;303:21-8.
32. Yu GP, Ji Y, Chen GQ, et al. Application of RUNX3 gene promoter methylation in the diagnosis of non-small cell lung cancer. Oncol Lett 2012;3:159-162.
33. Lu DG, Ji XQ, Liu W. Significance of RUNX3 Hypermethylation in Serum DNA of Non-small Cell Lung Cancer Patients. Cancer Research on Prevention and Treatment 2011;38:671-4.
34. Hou DR, Wang HZ. Analysis of promoter hypermethylation of Runx3 gene in non-small cell lung carcinoma. Progress in Modern Biomedicine 2009;9:3692-5.
35. Yanagawa N, Tamura G, Oizumi H, et al. Promoter hypermethylation of tumor suppressor and tumorrelated genes in non-small cell lung cancers. Cancer Sci 2003;94:589-92.
36. Suzuki M, Shigematsu H, Shames DS, et al. DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br J Cancer 2005;93:1029-37.
37. Yanagawa N, Tamura G, Oizumi H, et al. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer 2007;58:131-8.
38. Yoshino M, Suzuki M, Tian L, et al. Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers. Int J Oncol 2009;35:1201-9.
39. Li QL, Kim HR, Kim WJ, et al. Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun 2004;314:223-8.
40. Chung JH, Lee HJ, Kim BH, et al. DNA methylation profile during multistage progression of pulmonary adenocarcinomas. Virchows Arch 2011;459:201-11.
41. Omar MF, Ito K, Nga ME, et al. RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status. Pathol Oncol Res 2012;18:783-92.
42. Licchesi JD, Westra WH, Hooker CM, et al. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 2008;29:895-904.
43. Damaschke NA, Yang B, Bhusari S, et al. Epigenetic susceptibility factors for prostate cancer with aging. Prostate 2013;73:1721-30.
44. D'Aquila P, Rose G, Bellizzi D, et al. Epigenetics and aging. Maturitas 2013;74:130-6.
45. Waki T, Tamura G, Sato M, et al. Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples. Oncogene 2003;22:4128-33.